Navigation Links
Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
Date:12/23/2009

mportant class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin for weight management, has completed a pivotal Phase 3 clinical trial program. Arena submitted lorcaserin's New Drug Application to the FDA in December 2009.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the development, therapeutic indication and use, tolerability, safety, and efficacy of MK-1903; the discontinuation of Arena's collaboration with Merck; future collaborative activities; the regulatory approval of lorcaserin; and Arena's focus, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, regulatory authorities may not accept Arena's NDA submission; regulatory authorities may not find data from Arena's clinical trials and studies sufficient for regulatory approval; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its p
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
3. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
6. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
8. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
9. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
11. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... , August 31, 2015 , ... Frau   für chirurgische   Behandlung     ... 7-90   werden für eine   verheerende   Geburtsverletzung ... behandeln und die Anzahl ausgebildeter Chirurgen in Kenia bis ... gab heute bekannt, dass  Action on Fistula  seit ihrem ...
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is pleased to announce ... session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & Scientific Instruments ... and scientific instruments show which will be held at International Conference Hall in ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal Health ... animal health companies to hear from animal health companies with the newest technology. ... licensing agreements or distribution contracts. This meeting is one of the only ...
(Date:8/27/2015)... , Aug. 27, 2015 The National ... patient,s eyes—and life—were saved by doctors at Vanderbilt University ... with NNFF, NovaBay Pharmaceuticals and Dr. John Crew ... at Seton Medical Center in Daly ... used a breakthrough approach, pioneered by Dr. Crew, that ...
Breaking Biology Technology:Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... of Anesiva,s Needle-Free Technology, SOUTH SAN ... Anesiva, Inc. (Nasdaq: ANSV ) and ... entered into an,agreement granting Particle Therapeutics a ... into its needle-free,intradermal delivery system for glucagon, ...
... 30 Medarex, Inc.,(Nasdaq: MEDX ) announced today ... Partners Healthcare Conference at 11:30 AM Eastern Time on,Wednesday, ... the Four,Seasons Hotel in Boston, Massachusetts. Medarex,s presentation will ... the Webcast page in,the Investor Relations section of the ...
... Aug. 30 Micromet, Inc.,(Nasdaq: MITI ), ... proprietary antibody-based products for cancer, inflammation and,autoimmune diseases, ... Executive Officer of Micromet, will present at the ... on Wednesday,September 5, 2007 at 9:50am Eastern time ...
Cached Biology Technology:Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 2Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 3Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 4Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007 2Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... of the most frustrating problems faced by doctors who treat ... More than 38,000 people in the United States die of ... desperately needed. For almost three decades, scientists and physicians ... mutated in virtually all pancreatic cancers, making it an important ...
... known that large volcanic explosions can affect the weather ... the air. Some suspect that extended "volcanic winters" ... In the summer following Indonesia,s 1815 Tambora ... England, and the 1991 blowout of the Philippines, Mount ...
... Calif.Calcium regulates many critical processes within the body, including ... But too much calcium can be a bad thing. ... diseases, such as severe muscle weakness, a fatal reaction ... intense X-rays from the Stanford Synchrotron Radiation Lightsource (SSRL) ...
Cached Biology News:UNC team discovers promising target for new pancreatic cancer treatments 2Volcanic eruptions affect rainfall over Asian monsoon region 2Volcanic eruptions affect rainfall over Asian monsoon region 3X-rays offer first detailed look at hotspots for calcium-related disease 2
... NanoMate 100 robotic system and disposable ESI ... of the capabilities of electrospray mass spectrometers ... with MS allows users to either speed ... and peptide mapping applications, or long acquisition ...
... RTS AviTag E. coli Biotinylation Kit, Linear Template ... E. coli expression kits. (Cat. No. 3 186 ... to rapidly generate linear expression constructs by PCR ... on a combination of T7 RNA polymerase and ...
... enables sensitive and specific detection of microRNAs ... in situ detection probes have high binding ... sensitive detection of miRNAs. Specific in situ ... mounts, thin sections, single cells and in ...
... the major proteolytic system in the ... catalyzes the selective degradation of short-lived ... of proteins with abnormal conformation (Hershko ... critical protease in this pathway is ...
Biology Products: